Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Ferrero

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Biochemical and Biophysical Research Communications|July 25, 2014
Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcomeJ Doyen, C Trastour, F Ettore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-upJ M Ferrero, A Ramaioli, J L Formento, et al.
Bone Marrow Transplantation|February 28, 2006
Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre studyA Gonçalves, R Delva, M Fabbro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2006
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trialJ-M Ferrero, B Weber, J-F Geay, et al.
Oncology|October 5, 2011
A phase I study of UFT-oral vinorelbine in metastatic breast cancerJ M Ferrero, R Largillier, C Michel, et al.
Oncology|June 26, 2004
A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancerJ M Ferrero, C Foa, S Thezenas, et al.
Pharmacotherapy|December 17, 1997
Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factorsJ L Lagrange, B Médecin, M C Etienne, et al.
British Journal of Cancer|January 19, 2000
Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patientsJ M Ferrero, M C Etienne, J L Formento, et al.
Journal of Clinical Pathology|March 1, 1997
Non-specifically labelled cells that simulate bone marrow metastases in patients with non-metastatic breast cancerM Lagrange, J M Ferrero, J L Lagrange, et al.
British Journal of Cancer|March 4, 2010
Participants' uptake of clinical trial results: a randomised experimentJ Mancini, D Genre, F Dalenc, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Biochemical and Biophysical Research Communications|July 25, 2014
Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcomeJ Doyen, C Trastour, F Ettore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-upJ M Ferrero, A Ramaioli, J L Formento, et al.
Bone Marrow Transplantation|February 28, 2006
Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre studyA Gonçalves, R Delva, M Fabbro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2006
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trialJ-M Ferrero, B Weber, J-F Geay, et al.
Oncology|October 5, 2011
A phase I study of UFT-oral vinorelbine in metastatic breast cancerJ M Ferrero, R Largillier, C Michel, et al.
Oncology|June 26, 2004
A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancerJ M Ferrero, C Foa, S Thezenas, et al.
Pharmacotherapy|December 17, 1997
Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factorsJ L Lagrange, B Médecin, M C Etienne, et al.
British Journal of Cancer|January 19, 2000
Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patientsJ M Ferrero, M C Etienne, J L Formento, et al.
Journal of Clinical Pathology|March 1, 1997
Non-specifically labelled cells that simulate bone marrow metastases in patients with non-metastatic breast cancerM Lagrange, J M Ferrero, J L Lagrange, et al.
British Journal of Cancer|March 4, 2010
Participants' uptake of clinical trial results: a randomised experimentJ Mancini, D Genre, F Dalenc, et al.
Pageof 8